Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Company Overview

Webcast ImageWebcast
Pacira Pharmaceuticals, Inc. at Barclays Global Health Care Conference (Replay)
03/16/17 at 10:15 a.m. ET
Pacira Pharmaceuticals, Inc. at Barclays Global Health Care Conference
Thursday, March 16, 2017 10:15 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$48.15
Change (%) Stock is Up 1.40 (2.99%)
Volume901,444
Data as of 03/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
03/16/17Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide
Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities PARSIPPANY, N. J. and LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Trinity Health, one of the largest hospital systems in the nation, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced they will collaborate to develop an alternative approach to opioids for pain management. ... 
Printer Friendly Version
03/14/17Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty
Multicenter randomized study serves as unequivocal evidence of EXPAREL as an opioid minimizing agent in a complex and painful surgical procedure Protocol’s best practice infiltration technique for the use of EXPAREL will be focus of educational programs at American Academy of Orthopaedic Surgeons Annual Meeting PARSIPPANY, N.J. , March 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspensi... 
Printer Friendly Version
03/13/17Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its management team is scheduled to present at the Barclays Global Healthcare Conference at 10:15 a.m. ET on Thursday, March 16, 2017, in Miami. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two w... 
Printer Friendly Version
03/07/17Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Convertible Senior Notes due 2022
PARSIPPANY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced the pricing of $300 million aggregate principal amount of convertible senior notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).  Pacira also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $45 million aggregate princ... 
Printer Friendly Version

Corporate Presentation

DateTitle
03/13/17
Corporate Presentation
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com